Arsenic trioxide for the treatment of myelodysplastic syndromes

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.3, 2004-03, pp. : 613-621

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lenalidomide for Treatment of Myelodysplastic Syndromes

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3198-3203

Bentham Science Publishers

Access to resources Recommend Favorite

Arsenic trioxide in the treatment of haematological malignancies

By Kwong Yok-Lam

Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. : 589-597

Informa Healthcare

Access to resources Recommend Favorite

5-Azacytidine for the treatment of myelodysplastic syndromes

By Krawczyk Janusz Keane Niamh Freeman Ciara Louise Swords Ronan O'Dwyer Michael Giles Francis J

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 9, 2013-06 ,pp. : 1255-1268

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic spectrum in the treatment of myelodysplastic syndromes

By Hofmann Wolf-K Baldus Claudia Uharek Lutz Thiel Eckhard

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 12, 2004-12 ,pp. : 2451-2458

Informa Healthcare

Access to resources Recommend Favorite

The role of azacitidine in the treatment of myelodysplastic syndromes

By Abdulhaq Haifaa Rossetti James M

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 12, 2007-12 ,pp. : 1967-1975

Informa Healthcare

Access to resources Recommend Favorite